CTD Holdings, Inc., a family of biotechnology growth companies, said on Tuesday that it will ship an additional 608 vials of Trappsol Cyclo to the government of Brazil under a five-year business relationship.
Trappsol Cyclo is being developed for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children. It is being used as an investigational new drug for the treatment of NPC in the United States, Europe and Brazil. Trappsol Cyclo is the only commercial product to hold Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency as a treatment for NPC.
CTD has an exclusive supplier agreement with the government of Brazil. It supplies to the country through its exclusive distribution partner UnoHealthcare, based in Miami, Florida.
“We are grateful to be able to supply Brazilian NPC patients with Trappsol Cyclo,” CTD President and CEO Jeffrey Tate said. “Our exclusive agreement with UnoHealthcare for distribution in Brazil has been instrumental in getting this product in the hands of physicians for the benefit of their NPC patients.”
CTD will have supplied nearly 5,000 vials of liquid Trappsol Cyclo and more than 170 kg of powdered first-generation product to the government in Brazil for treatment of NPC after the delivery is completed. CTD has been supplying Trappsol Cyclo to Brazil for treatment of NPC since 2010.
